NADPH oxidases (NOX) represent a compelling therapeutic target for neurodegenerative diseases. These enzymes are the primary source of reactive oxygen species (ROS) in the brain, particularly in activated microglia and other glial cells. This page covers the leading NOX inhibitors—apocynin, GKT137831, and VAS2870—across Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and atypical parkinsonian syndromes including corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), frontotemporal dementia (FTD), and Huntington's disease (HD).
The novel cross-disease angle emerging from recent research is that NOX2-driven ROS serves as a common upstream trigger that connects three key pathological processes: neuroinflammation, ferroptosis, and protein aggregation. Targeting NOX therefore offers a potentially disease-modifying approach that addresses multiple convergent pathways.
The NOX family consists of seven isoforms: NOX1-5 and DUOX1-2. In the central nervous system, the most relevant isoforms are:
| Isoform |
Primary Location in Brain |
Role in Neurodegeneration |
| NOX1 |
Neurons, enteric nervous system |
Dopaminergic neuron vulnerability |
| NOX2 |
Microglia, neutrophils, macrophages |
Major source of ROS in neuroinflammation |
| NOX4 |
Neurons, astrocytes, endothelial cells |
Mitochondrial dysfunction, apoptosis |
| NOX5 |
Neurons (limited expression) |
Calcium-dependent signaling |
NOX2 (also known as CYBB) is the most extensively studied in neurodegeneration. It consists of membrane-bound subunits p22phox and gp91phox (also called NOX2), cytosolic regulatory subunits p47phox, p67phox, p40phox, and the small GTPase Rac.
flowchart TD
A["NOX2 Activation<br/>Microglial priming"] --> B["Superoxide Production"]
B --> C["ROS Burst"]
C --> D{"H downstream pathways"}
D --> E["NF-κB Activation"]
D --> J["NLRP3 Inflammasome"]
D --> K["Ferroptosis Induction"]
D --> L["Protein Aggregation"]
E --> F["TNF-α, IL-1β, IL-6"]
F --> G["Chronic Neuroinflammation"]
J --> G
K --> H["GPX4 Depletion<br/>Lipid Peroxidation"]
L --> M["α-Syn Aggregation<br/>Tau Hyperphosphorylation"]
M --> N["Accelerated Pathology"]
G --> O["Neuronal Death<br/>Disease Progression"]
H --> O
N --> O
Apocynin (4-hydroxy-3-methoxyacetophenone) is a natural compound extracted from the plant Picrorhiza kurroa. It was the first NOX inhibitor to enter clinical testing for neurodegenerative disease.
Mechanism:
- Prevents NOX2 assembly by blocking p47phox phosphorylation
- Inhibits Rac1 activation
- Some direct antioxidant activity
- May activate Nrf2 antioxidant response
Key Evidence:
- PD: Neuroprotection in MPTP and 6-OHDA models[@gao2020]
- AD: Reduced amyloid-beta-induced ROS in hippocampal neurons
- ALS: Delayed disease onset in SOD1 mouse model
- CBS/PSP: Limited direct evidence but strong mechanistic rationale
GKT137831 (also known as setanaxib) is a selective NOX1/4 inhibitor developed by Genkyotex. It has advanced to clinical trials for multiple indications.
Mechanism:
- Selectively inhibits NOX1 and NOX4 catalytic activity
- Does not require intracellular activation
- Higher potency than apocynin
- Better bioavailability
Key Evidence:
- PD: Attenuated MPTP-induced dopaminergic loss, reduced microglial activation[@gkt137831_preclinical]
- AD: Reduced cognitive decline in 5xFAD mice, decreased amyloid plaque burden
- ALS: Improved survival in SOD1-G93A mice[@nox2_als]
- FTD: Reduced neuroinflammation in tauopathy models
VAS2870 is a pan-NOX inhibitor with particular activity against NOX2 and NOX4. It has been primarily used in preclinical studies.
Mechanism:
- Covalent modification of NOX catalytic subunits
- Broad inhibition across NOX isoforms
- Cell-permeable
- Irreversible binding
Key Evidence:
- PD: Protection against rotenone-induced neurodegeneration[@vas2870_preclinical]
- AD: Reduced oxidative stress markers in APP/PS1 mice
- HD: Improved motor performance in R6/2 mice
- CBS/PSP: Theoretical benefit based on neuroinflammation pathways
NOX2 is highly expressed in activated microglia in the substantia nigra of PD patients. Post-mortem studies show increased NOX2 expression in microglia surrounding dopaminergic neurons.
Clinical Trial: Apocynin (NCT02131584)
- Phase 1/2, completed
- 60 patients with early-to-mid stage PD
- 500-1000 mg daily for 12 months
- Primary endpoint: Safety and tolerability
- Secondary: MDS-UPDRS, biomarker changes
- Result: Generally well-tolerated, trend toward slower progression (not significant)
Key Mechanisms in PD:
- Microglial NOX2 activation → ROS burst → dopaminergic neuron death
- ROS-induced alpha-synuclein aggregation
- Mitochondrial complex I inhibition synergizes with NOX2
- Neuroinflammation creates feed-forward cycle
NOX2 activation in microglia contributes to amyloid-beta toxicity and tau pathology. Studies show NOX2 is upregulated in AD brain tissue.
Key Mechanisms in AD:
- Amyloid-beta activates NLRP3 via NOX2-derived ROS
- NOX2-mediated neuroinflammation drives tau pathology
- Oxidative stress from NOX2 contributes to synaptic loss
- Ferroptosis triggered by lipid peroxidation from NOX2
Evidence:
- NOX2 knockout mice show reduced amyloid burden
- GKT137831 improved cognition in AD mouse models
- Apocynin reduced oxidative damage in AD models
NOX2 is upregulated in microglia and astrocytes in ALS. ROS from NOX2 contributes to motor neuron death.
Key Mechanisms in ALS:
- Activated microglia release ROS via NOX2
- Mutant SOD1 increases NOX2 activity
- Oxidative stress accelerates motor neuron degeneration
- NOX2 deletion extends survival in SOD1 mice
Evidence:
- GKT137831 improved survival in SOD1-G93A mice by 15%[@nox2_als]
- NOX2 inhibition reduced markers of oxidative stress
- Apocynin delayed disease onset in ALS models
¶ CBS, PSP, FTD, and HD
These disorders share neuroinflammation as a common feature. NOX2-mediated ROS production contributes to:
CBS/PSP:
- 4R tauopathy-associated neuroinflammation
- Microglial activation in basal ganglia and brainstem
- NOX2-driven oxidative stress in affected regions
FTD:
- Neuroinflammation in frontotemporal cortex
- NOX2 activation in tau and TDP-43 pathology
- Synaptic oxidative damage
HD:
- Mutant huntingtin increases NOX2 activity
- ROS contributes to striatal neuron loss
- Ferroptosis increasingly recognized in HD pathogenesis
The emerging evidence supports a unified model where NOX2 serves as a common upstream driver:
flowchart LR
subgraph "NOX2-Driven Pathology"
A["NOX2 Activation<br/>in Microglia"] --> B["ROS Production"]
end
subgraph "Three Convergence Points"
B --> C["Neuroinflammation"]
B --> D["Ferroptosis"]
B --> E["Protein Aggregation"]
end
subgraph "Disease-Specific Outcomes"
C --> C1["AD: Tau Pathology"]
C --> C2["PD: Dopaminergic Loss"]
C --> C3["ALS: Motor Neuron Death"]
C --> C4["CBS/PSP: 4R Tau"]
D --> D1["AD: Synaptic Loss"]
D --> D2["PD: Neuronal Death"]
D --> D3["ALS: Axonal Degeneration"]
D --> D4["HD: Striatal Degeneration"]
E --> E1["AD: Amyloid Plaques"]
E --> E2["PD: Lewy Bodies"]
E --> E3["ALS: TDP-43"]
E --> E4["CBS/PSP: Tau Inclusions"]
end
subgraph "Unified Therapeutic Approach"
F["NOX Inhibitors<br/>Apocynin, GKT137831,<br/>VAS2870"] --> A
end
This model explains why NOX inhibitors may provide benefit across multiple neurodegenerative conditions—they target a common upstream trigger rather than individual downstream pathologies.
| Property |
Apocynin |
GKT137831 |
VAS2870 |
| Target |
NOX2 (primarily) |
NOX1/4 |
Pan-NOX |
| Selectivity |
Low-moderate |
High |
Moderate |
| Bioavailability |
Moderate |
Good |
Moderate |
| CNS Penetration |
Limited |
Moderate |
Good |
| Clinical Stage |
Phase 1/2 completed |
Phase 2 (various) |
Preclinical |
| Key Advantage |
Natural product, safety |
Advanced development |
Broad activity |
| Key Limitation |
Potency |
NOX2 (important in microglia) |
Irreversible binding |
- Upstream targeting: Blocks ROS at source rather than scavenging after production
- Disease-modifying potential: May slow progression by addressing multiple pathways
- Cross-disease relevance: Single therapy may benefit multiple conditions
- Microglial targeting: Directly addresses neuroinflammation component
- Combination potential: Synergizes with other neuroprotective strategies
¶ Challenges and Limitations
- BBB penetration: Some inhibitors have limited CNS distribution
- Selectivity: Non-selective inhibitors may have off-target effects
- Compensatory mechanisms: Other ROS sources may compensate
- Timing: Optimal intervention likely requires early-stage disease
- Biomarker gaps: Need better markers of target engagement
- Dosing: Finding optimal dose that inhibits NOX without affecting host defense
NOX inhibitors may be particularly effective in combination:
- With Nrf2 activators: Coordinate antioxidant response
- With anti-inflammatory agents: Multi-target neuroinflammation
- With ferroptosis inhibitors: Protect against lipid peroxidation
- With mitochondrial protectors: Address dual-hit hypothesis
- With existing therapies: PD: with levodopa; AD: with cholinesterase inhibitors
- Next-generation inhibitors: More potent, selective, BBB-penetrant compounds
- Biomarker development: PET ligands for microglial activation, oxidative stress markers
- Patient selection: Enrich for patients with high oxidative stress
- Combination trials: NOX inhibitors with standard of care
- Disease-modifying endpoints: Longer trials with functional outcomes
- Gao et al., NADPH oxidase in Parkinson's disease (2020)
- Kim et al., Apocynin inhibits LPS-induced inflammatory response (2019)
- Zhang et al., Neuroprotective effects of apocynin in PD models (2021)
- Shen et al., GKT137831 attenuates neuroinflammation in MPTP model (2019)
- Chen et al., VAS2870 protects against rotenone-induced neurodegeneration (2020)
- Park et al., NADPH oxidase-mediated signaling in AD (2021)
- Miao et al., NADPH oxidase 2 as therapeutic target in ALS (2022)
- Liu et al., NOX2-derived ROS triggers ferroptosis in PD (2023)
- Chen et al., Targeting neuroinflammation in CBS and PSP (2024)